Index

Note: Page numbers of article titles are in boldface type.

A
ABO-incompatible LDLT, 654–655
ACLF. See Acute-on-chronic liver failure (ACLF)
Acute cellular rejection
after LT
impact on overall patient and graft survival
underlying liver disease effects on, 719–720
Acute kidney injury (AKI)
described, 543–544
Acute liver failure
adolescents with
LT for, 618–619
Acute-on-chronic liver failure (ACLF), 561–574
after LT
outcomes of, 571
decompensated cirrhosis vs., 562
definitions of, 567–569
APASL, 567
EASL-CLIF, 567
NACSELD, 568
regional differences in, 568–569
events precipitating, 563
introduction, 561–562
medical therapy for, 570–571
physiology of, 562–566
brain, 565
circulatory, 565–566
pulmonary, 566
renal, 564–565
predictive models of, 569–570
in pretransplant patients, 570
unsolved questions related to, 571–572
Adolescence
defined, 614
issues related to, 614
Adolescent(s)
LT in, 613–632
contraindications to, 621
indications for, 614–618
\(\alpha_1\)-antitrypsin deficiency, 615–616
acute liver failure, 618–619
Alagille syndrome, 616
Adolescent(s) (continued)

autoimmune liver disease types I and II, 617
biliary atresia, 615
CF, 616–617
CLIF, 614–615
drug-induced liver failure, 618
fibropolycystic liver disease, 617
inborn errors of metabolism, 619–620
inherited metabolic liver disease, 615–616
liver tumors, 620
PFIC1, 616
primary immunodeficiency, 617
tyrosinemia type I, 616
viral hepatitis, 618
Wilson disease, 617

introduction, 613–614
post-transplant management, 622
preparation for, 621–626
hepatic complications management in, 621
immunization in, 621
nutritional support in, 621
psychological, 621
pretransplant evaluation, 620–621
procedure, 621–622
risk factors affecting survival, 623–625
survival and quality of life, 622–623
timing of, 617–618
transition to adult care, 625–626

AIH. See Autoimmune hepatitis (AIH)
AKI. See Acute kidney injury (AKI)
Alagille syndrome
LT in adolescents for, 616
Alcohol-related cardiomyopathy
in LT candidates, 532–533
Alcoholic liver disease (ALD)
after LT
recurrence of, 679–680

ALD. See Alcoholic liver disease (ALD)
α1-Antitrypsin deficiency
LT in adolescents for, 615–616
APASL. See Asia Pacific Association for the Study of the Liver (APASL)
Asia Pacific Association for the Study of the Liver (APASL)
ACLF definition of, 567

Atresia
biliary
LT in adolescents for, 615
Autoimmune hepatitis (AIH)
after LT
recurrence of, 676–677
Autoimmune liver disease types I and II
LT in adolescents for, 617
Azotemia
  prerenal, 545

B

Biliary atresia
  LT in adolescents for, 615

C

CAD. See Coronary artery disease (CAD)
Calcineurin inhibitors (CNIs)
  in HCV patients
    impact on long-term outcomes of LT, 721
    immunosuppression related to minimization of
      in LT
        clinical observation of, 694
Cancer
  in LT donors, 641–643
Cardiomyopathy
  alcohol-related
    in LT candidates, 532–533
  cirrhotic
    in LT candidates, 531–532
Cardiovascular disease
  post-LT metabolic syndrome and, 726
CDC. See Centers for Disease Control and Prevention (CDC)
Centers for Disease Control and Prevention (CDC)
  classification of donors at increased risk of infection transmission, 640–641
CF. See Cystic fibrosis (CF)
Chronic liver failure (CLIF)
  ACLF definition of, 567
  LT in adolescents for, 614–615
Cirrhosis
  decompensated
    ACLF vs., 562
  ESLD and
    renal dysfunction related to, 544–545
    renal function estimation in, 544–545
  primary biliary
    after LT
      recurrence of, 677–678
Cirrhotic cardiomyopathy
  in LT candidates, 531–532
CIT. See Cold ischemia time (CIT)
CLIF. See Chronic liver failure (CLIF)
CLKT. See Combined liver-kidney transplant (CLKT)
CMV. See Cytomegalovirus (CMV)
CNIs. See Calcineurin inhibitors (CNIs)
Cold ischemia time (CIT)
  graft dysfunction related to
    in LT donors, 638
Combined liver-kidney transplant (CLKT)
  for renal dysfunction in ESLD and post–LT, 550
Combined liver–pancreas–small bowel transplant, 665
Concomitant lung conditions
  in LT candidates, 540
Coronary artery disease (CAD)
  preexisting
    in LT candidates, 530–531
Corticosteroid(s)
  in HCV patients
    impact on long-term outcomes of LT, 721
Crigler–Najjar type I
  LT in adolescents for, 620
Cystic fibrosis (CF)
  LT in adolescents for, 616–617
Cytomegalovirus (CMV)
  immunosuppression and, 672

D
De novo infection
  after LT
    treatment of, 587–588
    HBV core antibody-positive donors and, 587
Diabetes
  post-LT metabolic syndrome and, 724–725
Donor(s)
  LT. See Liver transplant (LT) donors
Drug-induced liver failure
  LT in adolescents for, 618
Dyslipidemia
  post-LT metabolic syndrome and, 725–726

E
EASL–CLIF. See European Association for the Study of the Liver (EASL)–CLIF
End-stage liver disease (ESLD)
  cirrhosis and
    renal function estimation in, 544–545
    model for
      history of, 520–521
    renal dysfunction in, 543–560
      cirrhosis related to, 544–545
      introduction, 543–544
      revised definition, 544
      RRT for, 550
      types of, 545–549
ESLD. See End-stage liver disease (ESLD)
European Association for the Study of the Liver (EASL)–CLIF
  ACLF definition of, 567
F
Fibropolycystic liver disease
    LT in adolescents for, 617

G
Graft-versus-host disease (GVHD)
    immunosuppression and, 670–671
GVHD. See Graft-versus-host disease (GVHD)

H
HBV. See Hepatitis B virus (HBV)
HCC. See Hepatocellular carcinoma (HCC)
HCV. See Hepatitis C virus (HCV)
Heart-related issues
    in LT candidates, 530–533. See also Liver transplantation (LT), candidates for, assessment of, cardiac issues in
Hemorrhagic hereditary telangiectasia
    in LT candidates, 538–540
Hepatic hydrothorax
    in LT candidates, 534–535
Hepatitis
    autoimmune
        after LT
            recurrence of, 676–677
    viral
        LT in adolescents for, 618
Hepatitis B core antibody-positive donors
de novo infection and, 587
Hepatitis B virus (HBV)
in LT donors, 638–639
in LT recipients
    antiviral management of
        recent advances in, 584–588
    recurrence of
        after LT
            treatment of, 587–588
        prevention of
            antiviral strategies in, 585–587
Hepatitis C virus (HCV)
immunosuppression in
    impact on long-term outcomes of LT, 721–723
in LT donors, 639–640
in LT recipients, 576–584
    antiviral management of, 576–584
    recurrence of
        diagnosis of, 576–578
        immunosuppression and reducing of, 693–694
        liver retransplant in, 735–736
        prevention of
Hepatitis (continued)
  antiviral treatment in, 578–580
  significant
    antiviral treatment for, 580–584
Hepatitis E virus (HEV)
  evolving epidemiology of, 588–589
  in LT recipients, 588–593
    described, 589–592
    donor-derived, 592–593
Hepatitis viruses. See also specific types, e.g., Hepatitis C virus (HCV)
  LT and, 575–601
    described, 575
    HBV, 584–588, 638–639
    HEV, 588–593
Hepatocellular carcinoma (HCC)
  LDLT for, 652–653
  LT for, 603–612
    very large tumors, 605–608
      downstaging, 606
        extended criteria–tumor size and number, 605–606
        tumor biology, 606–608
    very small tumors, 603–605
      waiting time, 608–610
Hepatopulmonary syndrome (HPS)
  in LT candidates, 535–536
Hepatorenal syndrome (HRS), 545–546
HEV. See Hepatitis E virus (HEV)
HIV. See Human immunodeficiency virus (HIV)
HPS. See Hepatopulmonary syndrome (HPS)
HRS. See Hepatorenal syndrome (HRS)
Human immunodeficiency virus (HIV)
  in LT donors, 640
Hydrothorax
  hepatic
    in LT candidates, 534–535
Hyperoxaluria
  primary
    LT in adolescents for, 620
Hypertension
  post-LT metabolic syndrome and, 726

I
Immunodeficiency
  primary
    LT in adolescents for, 617
Immunosuppression, 687–716
  current practices, 687–691
  impact on long-term outcomes of LT, 719–723
    in HCV patients, 721–723
minimization of
as transplant goal, 691–697
in adult transplant recipients, 694–696
with aim of decreasing adverse effects, 692–694
clinical observation of CNI immunosuppression in LT, 694
feasibility of, 697
overview of, 691–692
in pediatric population, 696–697
in MVTx and intestinal transplantation, 668–672
nonsurgical complications of, 668–672
CMV, 672
GVHD, 670–671
PTLD, 671–672
rejection, 668–669
personalization of, 697
tolerance to, 698–706
current clinical trials, 705–706
donor-specific
clinical and experimental approach to induction of, 698–699
conceptual approach to induction of, 698
experimental models in animals, 699–701
in humans, 701–703
lessons from tolerance in renal transplantation and quest for biomarkers, 703–705
Immunosuppression-induced kidney injury
reducing of, 692
Inborn errors of metabolism
in adolescents
LT for, 619–620
Infection(s)
de novo
after LT
treatment of, 587–588
HBV core antibody-positive donors and, 587
immunosuppression and
reducing of, 693
Interleukin-2 receptor inhibition
in HCV patients
impact on long-term outcomes of LT, 722
Intestinal failure
MVTx for, 662
Intestinal transplantation
contraindications to, 664
grafts for, 664–667
immunosuppression in, 668–672
indications for, 662–664
intestinal failure and, 662
outcomes of, 672–673
postoperative management, 667–668
surgical technique, 667
Intrinsic renal disease, 546–549
Isolated intestinal transplant, 665
K

Kidney injury

   immunosuppression-induced
      reducing of, 692
   in post–LT period, 550–555

L

LDLT. See Living donor liver transplantation (LDLT)

Liver assist devices
   for ACLF, 570–571

Liver disease(s)
   alcoholic
      after LT
         recurrence of, 679–680
   end-stage. See End-stage liver disease (ESLD)
   fibropolycystic
      LT in adolescents for, 617
   metabolic
      inherited
         LT in adolescents for, 615–616
   nonviral
      after LT
         recurrence of, 675–685. See also specific diseases and Nonviral liver diseases, after LT, recurrence of

Liver failure
   acute
      LT in adolescents for, 618–619
   acute-on-chronic, 561–574. See also Acute-on-chronic liver failure (ACLF)
   chronic. See Chronic liver failure (CLIF)
   drug-induced
      LT in adolescents for, 618

Liver retransplant, 731–751
   described, 731–733
   HCV recurrence and, 735–736
   liver allocation for, 736–738
   outcomes after
      achieving optimal, 740–743
      better donor grafts, 740
   prognosis after
      recipient characteristics determining, 739–740
   technical challenges of, 743–745
   timing of
      in patient survival, 738–739

Liver transplant (LT) donors
   disease transmission in
      CDC on, 640–641
      risk factors for, 638–643
      cancer, 641–643
      HCV, 639–640
HIV, 640
viral HBV, 638–639
expanded, 633–649
graft dysfunction in
risk factors for, 633–638
age-related, 633–634
CIT, 638
donation after cardiac death status, 635–636
steatosis, 636–638
quality of
spectrum of, 633–643
Liver transplantation (LT)
in adolescents, 613–632. See also Adolescence; Adolescent(s), LT in
allocations related to
future changes in, 525
candidates for
assessment of
cardiac issues in, 530–533
alcohol-related cardiomyopathy, 532–533
cirrhotic cardiomyopathy, 531–532
introduction, 529
posttransplant metabolic syndrome, 533
preexisting CAD, 530–531
pulmonary issues in, 533–540
concomitant lung conditions, 540
hemorrhagic hereditary telangiectasia, 538–540
hepatic hydrothorax, 534–535
HPS, 535–536
portopulmonary syndrome, 536–538
death after
causes of, 718–719
evolving trends in, 519–527. See also MELD score
history of, 519–520
introduction, 519
failure of
reasons for, 733–735
for HCC, 603–612. See also Hepatocellular carcinoma (HCC), LT for
hepatitis viruses and, 575–601. See also specific viruses
immunosuppression in
minimization of, 691–697. See also Immunosuppression, minimization of, as
transplant goal
indications for
rare, 681
living donor
challenges in, 651–660. See also Living donor liver transplantation (LDLT)
long-term outcomes after, 717–730
immunosuppression effects on, 719–723
improving, 717–730
introduction, 717–718
malignancy, 726–728
metabolic syndrome, 723–726. See also Metabolic syndrome, post-LT
Liver (continued)

rejection effects on, 719–723
nonviral liver diseases after
recurrence of, 675–685. See also specific diseases and Nonviral liver diseases, after
LT, recurrence of
outcomes of
ACLF and, 571
recipients of
hepatitis viruses in, 575–601. See also specific viruses
retransplant, 731–751. See also Liver retransplant

Liver tumors
LT in adolescents for, 620
Living donor liver transplantation (LDLT), 651–660
ABO-incompatible, 654–655
challenges in, 651–660
donor risk and complications with, 655–657
for HCC, 652–653
introduction, 651–652
LT. See Liver transplantation (LT)

M

Malignancy
immunosuppression and
reducing of, 693
as long-term outcome of LT, 726–728
MELD. See Model for end-stage liver disease (MELD)
MELD allocation policy
improving, 524–525
MELD score, 520–525
advantages of, 521
disadvantages of, 521–522
evidence-based modifications to, 523–524
exceptions to, 522–523
history of, 520–521
Metabolic liver disease
inherited
LT in adolescents for, 615–616
Metabolic syndrome
immunosuppression and
reducing of, 692–693
post-LT, 533
components of, 723–726
cardiovascular disease, 726
diabetes, 724–725
dyslipidemia, 725–726
hypertension, 726
obesity, 723–724
long-term mortality and graft loss related to, 723
MMF. See Mycophenolate mofetil (MMF)
Model for end-stage liver disease (MELD)
history of, 520–521
Modified MVTx
- postoperative management, 667–668
- surgical technique, 667

Multivisceral transplantation (MVTx), 661–674
- contraindications to, 664
- described, 665–666
- grafts for, 664–667
- immunosuppression in, 668–672
- indications for, 662–664
- intestinal failure and, 662
- introduction, 661–662
- modified, 667–668
- outcomes of, 672–673
- postoperative management, 667–668
- surgical technique, 667

MVTx. See Multivisceral transplantation (MVTx)

Mycophenolate mofetil (MMF)
- in HCV patients
  - impact on long-term outcomes of LT, 721

N

NACSELD. See North American Consortium for the Study of End-Stage Liver Disease (NACSELD)

NAFLD. See Nonalcoholic fatty liver disease (NAFLD)

Nonalcoholic fatty liver disease (NAFLD)
- after LT
  - recurrence of, 680–681

Nonviral liver diseases
- after LT
  - recurrence of, 675–685. See also specific diseases
    - AIH, 676–677
    - ALD, 679–680
    - introduction, 675–676
    - NAFLD, 680–681
    - PBC, 677–678
    - PSC, 678–679

North American Consortium for the Study of End-Stage Liver Disease (NACSELD)
- ACLF definition of, 568

O

Obesity
- post-LT metabolic syndrome and, 723–724

P

PBC. See Primary biliary cirrhosis (PBC)

PFIC1. See Progressive familial intrahepatic cholestasis 1 (PFIC1)

Portopulmonary syndrome
- in LT candidates, 536–538

Post–liver transplantation (LT) period
- kidney injury in, 550–555
- renal dysfunction in
Post–liver (continued)
  introduction, 543–544
  types of, 545–549
Posttransplant lymphoproliferative disease (PTLD)
  immunosuppression and, 671–672
Prerenal azotemia, 545
Primary biliary cirrhosis (PBC)
  after LT
    recurrence of, 677–678
Primary hyperoxaluria
  LT in adolescents for, 620
Primary immunodeficiency
  LT in adolescents for, 617
Primary sclerosing cholangitis (PSC)
  after LT
    recurrence of, 678–679
Progressive familial intrahepatic cholestasis 1 (PFIC1)
  LT in adolescents for, 616
PSC. See Primary sclerosing cholangitis (PSC)
PTLD. See Posttransplant lymphoproliferative disease (PTLD)
Pulmonary issues
  in LT candidates, 533–540. See also Liver transplantation (LT), candidates for, assessment of, pulmonary issues in

R
Rejection
  impact on long-term outcomes of LT, 719–723
Renal disease
  intrinsic, 546–549
Renal dysfunction
  in ESLD and post–LT, 543–560. See also End-stage liver disease (ESLD), renal dysfunction in; Post–liver transplantation (LT) period, renal dysfunction in
    types of, 545–549
Renal replacement therapy (RRT)
  for renal dysfunction in ESLD and post–LT, 550
Renal transplantation
  immunosuppression in
    tolerance to
      lessons applied to LT, 703–705
Retransplantation
  hepatic, 731–751. See also Liver retransplant
RRT. See Renal replacement therapy (RRT)

S
Steatosis
  graft dysfunction related to
    in LT donors, 636–638

T
T-cell–depleting therapies
  in HCV patients
impact on long-term outcomes of LT, 721–722
Transplantation. See specific types, e.g., Liver transplantation
Tumor(s)
  liver
    LT in adolescents for, 620
Tyrosinemia type I
  LT in adolescents for, 616

V
Viral hepatitis
  LT in adolescents for, 618
Virus(es)
  hepatitis
    LT and, 575–601. See also specific viruses

W
Wilson disease
  LT in adolescents for, 617